Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

Fusion Pharmaceuticals (FUSN) signed a definitive agreement with AstraZeneca (AZN) . Per the agreement terms, the pharma giant will acquire all outstanding shares of Fusion for $21 per share in cash, aggregating to $2.0 billion.Existing Fusion shareholders will also receive one non-tradeable contingent value right (CVR) per share, entitling the holder to receive an additional $3 per share tied to a regulatory milestone. Combining the upfront and maximum potential contingent value payments, the existing shar ...